ProTrials Named One of the Fastest-Growing Companies and a Top Women-Owned Business
Mountain View, CA
ProTrials Research Inc., announced that it has earned a spot for the third consecutive year on Inc. Magazine’s Inc. 5000, an exclusive list of the fastest growing private companies in the U.S., and the Silicon Valley/San Jose Business Journal’s top women-owned businesses, a list of the largest public and private Silicon Valley women-owned businesses. The contract research organization (CRO) achieved these rankings based on revenue figures.
Inc. 5000 companies are chosen based on company’s year over year revenue growth for the past three years. To be considered, companies must be U.S.-based and privately held, for profit and independent – not subsidiaries or divisions of other companies. The 5000 companies that made the list reported aggregate revenue of $214 billion and median three-year growth of 126 percent.
The Silicon Valley/San Jose Business Journal list of the top 25 women-owned businesses ranks area public and private women-owned companies according to revenue.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Beyond the Molecule: How Human-Centered Design Unlocks AI's Promise in Pharma
June 23rd 2025How human-centered AI that is focused on customer, user, and employee experience can drive real transformation in clinical trials and beyond by aligning intelligent technologies with the people who use them.
2025 DIA Annual Meeting: Why AI and Automation Are Set to Become the New Normal in Clinical Research
June 20th 2025Peter Ronco, CEO, Emmes, shares his long-term vision for artificial intelligence in clinical research, from making automation routine to improving drug discovery, transforming regulatory oversight, reducing animal testing, and promoting ethical, equitable data use worldwide.
